2. 1
2
To the extent any statements made in this presentation contain information that is not historical, these statements are
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements
on our current expectations and projections about future events. Our actual results could differ materially from those
discussed in, or implied by, these forward-looking statements.
Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will,"
"may" and other similar expressions. In addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking statements. Forward-looking statements
include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U.S. Food and
Drug Administration and Canadian Therapeutic Products Directorate approvals, acceptance and demand for new
pharmaceutical products, the impact of competitive products and pricing, new product development and launch,
reliance on key strategic alliances, availability of raw materials and finished products, the regulatory environment, tax
rate assumptions, the outcome of legal proceedings, fluctuations in operating results and other risks detailed from
time to time in the Company's filings with the Securities and Exchange Commission and the Ontario Securities
Commission. IntelGenx undertakes no obligation to update or revise any forward-looking statement.
2
Forward Looking Statements
3. 2
2
3
Oral Thin Films
Oral Thin Films Provide
Significant Market Opportunities
for Improving Drug Delivery
• IntelGenx CEO co-developer of the
Listerine breath strips
• Oral films provide quicker action to relieve
symptoms
• IntelGenx’s goal to become a leader in
pharmaceutical oral film development &
manufacturing
5. 4
5
Strong Demographics for Oral Films
Many patient applications are compatible
with oral film characteristics
• Those who have difficult swallowing large pills:
pediatric, geriatric, or dysphagic
• North Americans over 65 will grow from 54MM to 85MM
over the next 15 years
• Patients who suffer gastrointestinal (GI) side effects
from their medication
• Normal patients who would prefer a more discrete
or pleasant administration of the drug
6. 5
A Robust Product Pipeline to Address
Significant Market Opportunities
Indication
Partnering
Availability
Formulation
Development
Pilot
Study
Pivotal
Study
Filing Launch
Films Migraine – Rizaport TM -
Rizatriptan
Available
except Spain
Erectile Dysfunction -
Tadalafil
Available
Schizophrenia - Loxapine Available
Central Nervous System -
Montelukast
Available
Respiratory (Cough & Cold) In Discussion
Cardiovascular In Discussion
Opioid Dependence
Par
Pharmaceutical
Undisclosed Term Sheet
Pain Term Sheet
Central Nervous System Term Sheet
5 6
7. 6
7
For Migraines
Leverages VersaFilm™ Technology
• European Mktg Approval – November 2015
• Co-development partnership with RedHill Biopharma
• Definitive agreement signed July 2016 with
Grupo Juste for Spain & additional territories
• Actively pursuing several opportunities to open new
markets - negotiations with future commercialization
partners ongoing
• Planned USA submission to FDA Q1/2017
• Expected USA launch Q3/2017
8. 7
For Erectile Dysfunction
• The first oral thin film using IntelGenx
proprietary drug delivery technology,
VersaFilm™, for ED
• Containing tadalafil (Cialis® - Eli Lilly),
a major molecule in the ED market
• Demonstrated bioequivalence to Cialis®
• Orally disintegrating films without need
for water provide unprecedented patient
convenience and a discrete dosing
alternative
• 505(b)(2) USA NDA submission in
Q1/2017
• Expected USA launch Q1/2018
8
9. 8
For Schizophrenia &
Bipolar 1 Disorder
9
• The first oral thin film using IntelGenx
proprietary drug delivery technology,
VersaFilm™, for Schizophrenia & Bipolar
1 disorder
• Fast-acting loxapine oral dosage – to
treat acute agitation with Schizophrenia &
Bipolar 1 disorder in non-institutionalized
patients
• Reduces risk of pulmonary problems
and potential risk of violence and injury to
patients and others
• Formulation optimization stage – results
expected Q2 2017
10. 9
For Mild Cognitive Impairment
• IntelGenx is repurposing Montelukast
for the treatment of MCI by leveraging
its VersaFilm™ technology
• The drug is known and approved
completely for a different indication
• Strong preclinical experience
• Phase 1 clinical trials started June 2016
with expected results September 2016
• Phase 2A clinical trial to begin Q4 2016
• Looking for a commercial partner
10
12. 11
Strengthened Management Team
Over 20 Employees, including 7 with Ph.D.’s
Andre Godin, CPA, CA
Executive VP, CFO
• 25+ years biotech/pharma
industry experience
• Member of the Canadian
Chartered Professional
Accountants and the
Canadian Institute of
Chartered Accountants
Nadine Paiement, M. Sc.
VP, Research & Development
• Co-inventor of IntelGenx
Trilayer Technology
• 15 years experience in
product development and
technology transfer
Edward Miller, B. Comm
Director, Investor Relations
• 15 years experience in
investor relations
• 10 + years experience in
pharmaceutical / biotech
Horst G. Zerbe, Ph. D.
Chairman, President & CEO
• Co-Founder of Listerine
breath strips
• 30+ years drug delivery /
pharma experience
• Holds over 40 patents in drug
delivery and numerous
scientific publications
12
Dana Matzen, Ph.D.
VP, Business & Corporate
Development
• 15 years experience in
pharmaceutical product
licensing
• Prev. Director, BD at Paladin
• Completed 13 transaction,
7 new product launches
John Durham, B. Sc.
VP, Operations
• 20+ years experience in
pharmaceutical
manufacturing, quality
management, product
development
• Held executive positions with
several Canadian and US
companies
13. 12
13
Completion of Construction
of Manufacturing Facility
• 17,000 sq ft facility in Montreal -
construction completed in Q1 2016
• Facility to be fully operational by Q1 2017
• High capacity manufacturing and
packaging equipment
• Lower costs, controls quality
and de-risks investment
for new products
GROSS MARGINS of 40% PLUS
We have built a state-of-the-art
oral film development and manufacturing facility
14. 13
14
We are Now Poised for Success
We are focused on areas where oral films
are particularly well-suited:
Develop and commercialize products that provide tangible patient benefits
leveraging oral films, such as:
• Reduced side effects
• Improved bio-availability
• Response time versus existing drugs
• Lifecycle management
• Repurpose existing drugs for new indications using oral films
• “First-to-file” Generic drugs where high technology barriers to
entry exist in reproducing branded films
15. 14
15
What Makes IntelGenx the Best in Oral Films
1. History
• Dr. Zerbe a pioneer with over 30 plus years in oral films
2. Formulation Team
• Strong in applying biopharmaceutical aspects to formulation development
• Top quality scientists: highly creative, focused on problem solving & innovative approaches
• Experienced in developing films for oral (GI), sublingual & buccal absorption
3. Competitive Manufacturing Capabilities
• First in Canada
• New state-of-the-art manufacturing facility
• Offer one-stop-shopping to our partners with lean operations keeping costs down
• Customized manufacturing equipment
18. 17
Net Comprehensive Income & Adjusted EBITDA ($M)
-1.5
-0.6
0.8
-2.2
-1.2
-0.1
1.7
-1.6
-2.5
-2
-1.5
-1
-0.5
0
0.5
1
1.5
2
H1 2016 H1 2015 2015 Full Year 2014 Full Year
Net Income Adjusted EBITDA
$M
Financial Performance
18
19. 18
Monetization of Forfivo Future Royalties
for $6 Million
• IntelGenx made a strategic decision to become completely focused on Oral Films
• Sale of Forfivo XL Royalty for $6M (CAD$8M) to SWK Holdings – August 5, 2016
• Largest influx of cash in history of corporation
• Non-dilutive source of cash to strengthen balance sheet
• SWK receives 100% of all royalties as of April 1, 2016
• SWK will have 100% of the $2 million milestone for net sales reaching $15M
• SWK will have 35% of all future milestones
19
21. 20
21
Solid Platform for Growth
Significant Market Potential
• New manufacturing facility will offer many competitive advantages
• Strengthened management team to accelerate execution of business plan
• Implemented product sourcing strategy to identify high-value product opportunities
• Building strategic partnerships with relevant partners in the pharmaceutical industry
Solid Platform for Growth
